Literature DB >> 10768972

Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection.

R Weltzin1, B Guy, W D Thomas, P J Giannasca, T P Monath.   

Abstract

The heat-labile toxin (LT) of Escherichia coli is a potent mucosal adjuvant that has been used to induce protective immunity against Helicobacter felis and Helicobacter pylori infection in mice. We studied whether recombinant LT or its B subunit (LTB) has adjuvant activity in mice when delivered with H. pylori urease antigen via the parenteral route. Mice were immunized subcutaneously or intradermally with urease plus LT, recombinant LTB, or a combination of LT and LTB prior to intragastric challenge with H. pylori. Control mice were immunized orally with urease plus LT, a regimen shown previously to protect against H. pylori gastric infection. Parenteral immunization using either LT or LTB as adjuvant protected mice against H. pylori challenge as effectively as oral immunization and enhanced urease-specific immunoglobulin G (IgG) responses in serum as effectively as aluminum hydroxide adjuvant. LT and LTB had adjuvant activity at subtoxic doses and induced more consistent antibody responses than those observed with oral immunization. A mixture of a low dose of LT and a high dose of LTB stimulated the highest levels of protection and specific IgG in serum. Urease-specific IgG1 and IgG2a antibody subclass responses were stimulated by all immunization regimens tested, but relative levels were dependent on the adjuvant used. Compared to parenteral immunization with urease alone, LT preferentially enhanced IgG1, while LTB or the LT-LTB mixture preferentially enhanced IgG2a. Parenteral immunization using LT or LTB as adjuvant also induced IgA to urease in the saliva of some mice. These results show that LT and LTB stimulate qualitatively different humoral immune responses to urease but are both effective parenteral adjuvants for immunization of mice against H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768972      PMCID: PMC97487          DOI: 10.1128/IAI.68.5.2775-2782.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  67 in total

1.  Skin immunization made possible by cholera toxin.

Authors:  G M Glenn; M Rao; G R Matyas; C R Alving
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

2.  Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.

Authors:  C Czerkinsky; M W Russell; N Lycke; M Lindblad; J Holmgren
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

3.  Pathophysiologic effects of lethal and immunoregulatory doses of cholera enterotoxin in the mouse.

Authors:  F V Chisari; R S Northrup
Journal:  J Immunol       Date:  1974-09       Impact factor: 5.422

4.  Gangliosides and membrane receptors for cholera toxin.

Authors:  P Cuatrecasas
Journal:  Biochemistry       Date:  1973-08-28       Impact factor: 3.162

5.  Adjuvant effect of cholera enterotoxin on the immune response of the mouse to sheep red blood cells.

Authors:  R S Northrup; A S Fauci
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

Review 6.  New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development.

Authors:  M M Levine; J B Kaper; R E Black; M L Clements
Journal:  Microbiol Rev       Date:  1983-12

7.  Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus.

Authors:  X P Liang; M E Lamm; J G Nedrud
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

Review 8.  What role does Helicobacter pylori play in gastric cancer?

Authors:  M Asaka; H Takeda; T Sugiyama; M Kato
Journal:  Gastroenterology       Date:  1997-12       Impact factor: 22.682

9.  Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses.

Authors:  J L Grun; P H Maurer
Journal:  Cell Immunol       Date:  1989-06       Impact factor: 4.868

10.  Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin.

Authors:  J J Guidry; L Cárdenas; E Cheng; J D Clements
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

View more
  25 in total

1.  Expression, purification and immuno-characteristics of recombination UreB protein of H.pylori.

Authors:  C Wu; Q M Zou; H Guo; X P Yuan; W J Zhang; D S Lu; X H Mao
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model.

Authors:  Rodolfo E Bégué; Halina Sadowska-Krowicka
Journal:  FEMS Immunol Med Microbiol       Date:  2010-08-23

3.  Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants.

Authors:  Rodolfo E Bégué; Alyson Moll
Journal:  Open Vaccine J       Date:  2009-01-01

4.  Analysis of immune responses against H pylori in rabbits.

Authors:  Khademul Islam; Ibrahim Khalil; Chowdhury Rafiqul Ahsan; Mahmuda Yasmin; Jamalun Nessa
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

5.  Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.

Authors:  Haibo Li; Jinyong Zhang; Yafei He; Bin Li; Li Chen; Weiwei Huang; Quanming Zou; Chao Wu
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

6.  Antigen 43/Fcε3 chimeric protein expressed by a novel bacterial surface expression system as an effective asthma vaccine.

Authors:  Feng-Ying Huang; Cai-Chun Wang; Yong-Hao Huang; Huan-Ge Zhao; Jun-Li Guo; Song-Lin Zhou; Hua Wang; Ying-Ying Lin; Guang-Hong Tan
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

7.  Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.

Authors:  Michael Kotiw; Megan Johnson; Manisha Pandey; Scott Fry; Stuart L Hazell; Hans J Netter; Michael F Good; Colleen Olive
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

8.  Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium.

Authors:  M Ghaem-Maghami; C P Simmons; S Daniell; M Pizza; D Lewis; G Frankel; G Dougan
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

9.  Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis.

Authors:  Frank Sommer; Henning Wilken; Gerhard Faller; Michael Lohoff
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen.

Authors:  Patricia Londoño-Arcila; Donna Freeman; Harry Kleanthous; Aisling M O'Dowd; Susan Lewis; Arthur K Turner; Emma L Rees; Timothy J Tibbitts; Judith Greenwood; Thomas P Monath; Michael J Darsley
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.